Cargando…
P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429152/ http://dx.doi.org/10.1097/01.HS9.0000847344.35314.45 |
| _version_ | 1784779348085047296 |
|---|---|
| author | wang, T. sun, X. qiu, L. su, H. cao, J. li, Z. song, Y. zhang, L. yi, S. qiu, L. zhou, J. wu, H. zhang, W. li, J. zhou, K. zhou, H. yang, Y. li, Z. cen, H. cai, Z. zhang, Z. fu, W. jin, J. li, F. wu, W. gu, X. zhu, W. liu, L. li, Z. |
| author_facet | wang, T. sun, X. qiu, L. su, H. cao, J. li, Z. song, Y. zhang, L. yi, S. qiu, L. zhou, J. wu, H. zhang, W. li, J. zhou, K. zhou, H. yang, Y. li, Z. cen, H. cai, Z. zhang, Z. fu, W. jin, J. li, F. wu, W. gu, X. zhu, W. liu, L. li, Z. |
| author_sort | wang, T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429152 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94291522022-08-31 P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL wang, T. sun, X. qiu, L. su, H. cao, J. li, Z. song, Y. zhang, L. yi, S. qiu, L. zhou, J. wu, H. zhang, W. li, J. zhou, K. zhou, H. yang, Y. li, Z. cen, H. cai, Z. zhang, Z. fu, W. jin, J. li, F. wu, W. gu, X. zhu, W. liu, L. li, Z. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429152/ http://dx.doi.org/10.1097/01.HS9.0000847344.35314.45 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters wang, T. sun, X. qiu, L. su, H. cao, J. li, Z. song, Y. zhang, L. yi, S. qiu, L. zhou, J. wu, H. zhang, W. li, J. zhou, K. zhou, H. yang, Y. li, Z. cen, H. cai, Z. zhang, Z. fu, W. jin, J. li, F. wu, W. gu, X. zhu, W. liu, L. li, Z. P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL |
| title | P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL |
| title_full | P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL |
| title_fullStr | P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL |
| title_full_unstemmed | P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL |
| title_short | P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL |
| title_sort | p1119: the oral pi3kδ inhibitor linperlisib for the treatment of relapsed or refractory follicular lymphoma: a single-arm multicenter phase 2 clinical trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429152/ http://dx.doi.org/10.1097/01.HS9.0000847344.35314.45 |
| work_keys_str_mv | AT wangt p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT sunx p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT qiul p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT suh p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT caoj p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT liz p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT songy p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhangl p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT yis p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT qiul p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhouj p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT wuh p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhangw p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT lij p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhouk p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhouh p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT yangy p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT liz p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT cenh p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT caiz p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhangz p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT fuw p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT jinj p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT lif p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT wuw p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT gux p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT zhuw p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT liul p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial AT liz p1119theoralpi3kdinhibitorlinperlisibforthetreatmentofrelapsedorrefractoryfollicularlymphomaasinglearmmulticenterphase2clinicaltrial |